
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
RAHWAY, NJ and TOKYO, Mar 2, 2026 – (JCN Newswire via SeaPRwire.com) – Merck & Co., Inc., Rahway, NJ, USA […]